Chemosensitization and mitigation of Adriamycin-induced cardiotoxicity using combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin in ovarian cancer

Publication date: Available online 22 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Adel Al Fatease, Vidhi Shah, Duc X. Nguyen, Brianna Cote, Nicole LeBlanc, Deepa A. Rao, Adam WG AlaniAbstractThis work looks to improve the efficacy of Adriamycin (ADR) while mitigating its cardiotoxicity using combinations of micellar resveratrol (R): quercetin (Q) (mRQ) or R: curcumin (C) (mRC) in healthy mice and ovarian cancer xenograft models. Ovarian cancer cells, ES2-Luc, or A2780ADR are inoculated in mice (n = 4/group) and sorted into eight cohorts. Mice are treated weekly for 4 weeks with ADR, ADR + mRQ, ADR + mRC, or controls (saline, empty micelles, ADR + EM, mRQ, or mRC). To evaluate the degree of cardioprotection, serum is collected to determine the cardiac Troponin I (cTnI). Cardiac tissue is collected for morphological evaluation and evaluation of creatine kinase levels. Our results indicate that mRQ + ADR is statistically significant in tumor reduction in xenograft models. In healthy mice, the left ventricular ejection fraction and fractional shortening in the ADR treated group is most compromised. Co-administration of mRQ with ADR can reduce ADR dosing through chemosensitization while being cardioprotective.Graphical AbstractAdriamycin is an effective antineoplastic agent that is widely used for ovarian and other cancers treatment. However, the full therapeutic potential of this drug is not...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research